DV Trading’s Eupraxia Pharmaceuticals EPRX Stock Holding History

DV Trading’s Portfolio EPRX Stock Details EPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-276,000	Closed	-$2M	–	723
2026 Q1	$2M	Buy	+276,000	New	+$2.22M	0.05%	114

Other funds holding EPRX

Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Balyasny Asset Management

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

DV Trading's EPRX Position: Q2 2026 in Review

DV Trading sold out of Eupraxia Pharmaceuticals (EPRX) in Q2 2026, closing a stake of 276,000 shares — an estimated $2M sold.

DV Trading first reported a position in EPRX in Q1 2026 and held it in 1 quarter. The position peaked at $2M in Q1 2026. 68 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

DV Trading reported no remaining Eupraxia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
DV Trading sold 276,000 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $2M.
DV Trading first reported a position in Eupraxia Pharmaceuticals in Q1 2026 and held it in 1 quarter.
DV Trading's Eupraxia Pharmaceuticals position peaked at $2M in Q1 2026.
68 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on DV Trading's 13F filing for Q2 2026, filed 14 Aug 2026.